Drug Trial Radar · NCT03779113
An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
69
Actual
Start
Sep 26, 2019
Primary completion
Feb 26, 2025
Study completion Feb 26, 2025
Sponsor
- Lead sponsor
- HutchmedIndustry
- Sponsor type
- Industry
- First posted
- Dec 19, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I, open-label, multicenter study of HMPL-523 administered orally to patients with relapsed or refractory lymphoma who have exhausted approved therapy options. This study consists of a dose escalation stage (Stage1) and a dose expansion stage (Stage 2).
Conditions
- Non Hodgkin Lymphoma
Interventions
HMPL-523Drug
Oral HMPL-523
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs)Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
- Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment DiscontinuationTime frame: From the first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment, approximately 29 months
- Dose Escalation Stage: Recommended Phase 2 Dose of HMPL-523Time frame: From the first dose of study treatment (Day 1) up to Day 28 of Cycle 1 (each cycle was 28 days)
- Dose Expansion Stage: Objective Response Rate (ORR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
- Dose Expansion Stage: Complete Response RateTime frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
- Dose Expansion Stage: Clinical Benefit Rate (CBR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
- Dose Expansion Stage: Duration of Response (DOR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
- Dose Expansion Stage: Time to Response (TTR)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
- Dose Expansion Stage: Progression-Free Survival (PFS)Time frame: Tumor assessments performed every 8 weeks (+/-7 days) for the first 24 weeks and every 12 weeks (+/-7 days) thereafter until first progression, initiation of new anticancer therapy or death. Approximately 42 months
Locations
32 sites in 7 countries. Site status is shown where the registry gives one.
Pacific Cancer Medical Center, Inc.
Anaheim, California
Innovative Clinical Research Institute
Downey, California
Ventura County Hematology-Oncology Specialists
Oxnard, California
Summit Medical Group
Florham Park, New Jersey
Clinical Research Alliance
New Hyde Park, New York
Leo Jenkins Cancer Center/ECU School of Medicine
Greenville, North Carolina
The University of Texas MD Anderson Cancer Center
Houston, Texas
Renovatio Clinical
The Woodlands, Texas
Aarhus University Hospital
Aarhus, Denmark
Helsingin yliopistollinen keskussairaala
Helsinki, Finland
Tampereen yliopistollinen sairaala
Tampere, Finland
CHU Clermont Ferrand - Hôpital d'Estaing
Clermont-Ferrand, France
Hôpital Henri Mondor
Créteil, France
Groupe Hospitalier Pitie-Salpetriere
Paris, France
CHU Poitiers - Hôpital la Milétrie
Poitiers, France
Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
Monza, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
Bergamo, Bergamo, Italy
Ospedale San Raffaele
Milan, Milano, Italy
KO-MED Centra Kliniczne
Biała Podlaska, Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, Poland
Nasz Lekarz Przychodnie Medyczne
Torun, Poland
Uniwersytecki Szpital Kliniczny im. Jana Mikulicza Radeckiego
Wroclaw, Poland
Hospital Universitari Vall d'Hebron
Barcelona, Spain
ICO Badalona - Hospital Universitari Germans Trias i Pujol
Barcelona, Spain
Institut Català d'Oncologia
Barcelona, Spain
Hospital Universitario Ramon y Cajal
Madrid, Spain
Fundacion Jimenez Diaz
Madrid, Spain
Hospital Universitario Infanta Leonor
Madrid, Spain
Hospital Universitario Quironsalud Madrid
Madrid, Spain
MD Anderson Cancer Centre
Madrid, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Hospital Universitario Virgen Macarena
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.